Department of Medicine.
Harvard Medical School, Boston, Massachusetts, USA.
Curr Opin Hematol. 2018 Mar;25(2):67-74. doi: 10.1097/MOH.0000000000000407.
This review summarizes the hallmark developments in induction chemotherapy for acute myeloid leukaemia and further describes future directions in its evolution.
We describe the origin of induction chemotherapy. We also describe notable modifications and adjustments to 7+3 induction chemotherapy since its development. Finally, we describe new efforts to modify and add new agents to induction therapy, including '7+3 Plus' combinations.
Induction chemotherapy remains the standard of care for the majority of patients with acute myeloid leukaemia. However, its success is limited in a subset of patients by toxicity, failure to achieve remission and potential for subsequent relapse. Novel agents such as mutant fms like tyrosine kinase 3 inhibitors, mutant isocitrate dehydrogenase inhibitors, CD33-antibody drug conjugates and liposomal formulations have demonstrated significant potential as modifications to traditional induction chemotherapy.
本文总结了急性髓系白血病诱导化疗的标志性进展，并进一步描述了其未来的发展方向。
我们描述了诱导化疗的起源。我们还描述了自诱导化疗发展以来，其在 7+3 方案基础上的显著改进和调整。最后，我们描述了为了改良诱导化疗并添加新药物所做的新努力，包括“7+3 联合方案”。
诱导化疗仍然是大多数急性髓系白血病患者的标准治疗方法。然而，由于毒性、缓解失败和随后复发的可能性，其在一部分患者中的疗效有限。新型药物如突变型 fms 样酪氨酸激酶 3 抑制剂、突变型异柠檬酸脱氢酶抑制剂、CD33 抗体药物偶联物和脂质体制剂已被证明具有作为传统诱导化疗改良剂的巨大潜力。
